AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$7.90
−$0.09 (−1.07%) 4:00 PM ET
After hours$7.89
−$0.00 (−0.06%) 3:47 AM ET
Prev closePrevC$7.98
OpenOpen$7.97
Day highHigh$8.06
Day lowLow$7.71
VolumeVol3,499,716
Avg volAvgVol6,549,302
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.85B
P/E ratio
11.61
FY Revenue
$509.86M
EPS
0.68
Gross Margin
61.27%
Sector
Healthcare
AI report sections
MIXED
ADMA
ADMA Biologics, Inc.
ADMA combines high margins, positive earnings, and low leverage with sharp recent share price declines and heavy downside momentum. Valuation appears moderate on earnings and EBITDA metrics but is offset by very low free cash flow yield and a notable drop in net income growth. Elevated short interest and a newly disclosed securities investigation add incremental sentiment and headline risk around an otherwise profitable operating profile.
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics (NASDAQ: ADMA) following allegations of channel stuffing to inflate revenue growth. A short seller report by Culper Research triggered a 16.6% stock decline on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.
ADMAsecurities fraudchannel stuffingclass action lawsuitshort seller allegationsinvestor lossesmisleading business information
Sentiment note
Company faces serious allegations of channel stuffing and issuing materially misleading business information, resulting in a significant 16.6% stock price decline and triggering a securities class action investigation.
NegativeGlobeNewswire Inc.• Rosen Law Firm
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.
IBRXADMASRADsecurities class actionfalse statementslead plaintiffinvestor lossescontingency fee
Sentiment note
Company is under investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, indicating alleged shareholder harm.
NegativeGlobeNewswire Inc.• The Rosen Law Firm
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics (NASDAQ: ADMA) following allegations of channel stuffing to inflate revenue growth. A short seller report by Culper Research triggered a 16.6% stock decline on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.
ADMAsecurities fraudchannel stuffingclass action lawsuitinvestor lossesshort seller reportmisleading business information
Sentiment note
Company faces allegations of channel stuffing and issuing materially misleading business information, resulting in a significant 16.6% stock price decline and triggering a securities class action investigation.
NeutralThe Motley Fool• Jonathan Ponciano
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
B Group, Inc. initiated a new position in Bright Minds Biosciences by purchasing 67,500 shares worth approximately $5.43 million in Q1 2026. The investment signals confidence in the company's epilepsy drug pipeline, particularly BMB-101. Bright Minds is a pre-clinical biotech firm with a well-funded balance sheet (C$309.7 million in cash) and no commercial revenue, representing a high-risk, high-reward opportunity for long-term investors.
Mentioned as B Group's top holding (21.4% of AUM) but no specific news or developments are discussed in the article. Inclusion is purely informational regarding fund composition.
NeutralThe Motley Fool• Jonathan Ponciano
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year
B Group increased its position in ADMA Biologics by 750,000 shares ($11.84 million) in Q1 2026, bringing its total stake to 3.2 million shares worth $28.90 million (21.4% of AUM). Despite ADMA shares falling 58% over the past year, the fund's confidence appears justified by Q1 results showing flat revenue but 22% growth in adjusted net income and 24% EBITDA growth, driven by strong 28% year-over-year growth in ASCENIV sales.
Mixed signals: stock down 58% year-over-year indicating negative market sentiment, but Q1 results show operational strength with improved profitability metrics (22% adjusted net income growth, 24% EBITDA growth) and strong ASCENIV revenue growth (28% YoY). Fund's increased investment suggests contrarian confidence in long-term recovery despite near-term headwinds from pricing pressure and BIVIGAM weakness.
NegativeGlobeNewswire Inc.• The Rosen Law Firm
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics (NASDAQ: ADMA) following allegations of channel stuffing to inflate revenue. A short seller report by Culper Research triggered a 16.6% stock decline on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.
ADMAsecurities fraudchannel stuffingclass action lawsuitshort seller reportinvestor lossesmisleading business information
Sentiment note
Company faces serious allegations of channel stuffing and issuing materially misleading business information, resulting in a significant 16.6% stock price decline and triggering a securities class action investigation.
NegativeGlobeNewswire Inc.• Rosen Law Firm
חדשות למשקיעים ב-ADMA: אם סבלתם הפסדים ב-ADMA Biologics, Inc (נאסד"ק: ADMA), אתם מוזמנים ליצור קשר עם משרד רוזן עורכי הדין בנוגע לזכויותיכם
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics, Inc. (NASDAQ: ADMA) following allegations of materially misleading business information. The investigation was triggered by a Culper Research report accusing the company of 'channel stuffing' to inflate revenue growth, which caused ADMA's stock to plunge 16.6% on March 24, 2026.
The company faces serious allegations of providing materially misleading business information to investors, specifically regarding revenue growth through channel stuffing practices. The resulting 16.6% stock price decline and ongoing securities investigation indicate significant reputational and legal risks.
NegativeGlobeNewswire Inc.• The Rosen Law Firm
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm announced an investigation into ADMA Biologics (NASDAQ: ADMA) following allegations of materially misleading business information. Short seller Culper Research released a report claiming the company engaged in channel stuffing to inflate revenue growth, causing ADMA shares to plunge 16.6% on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.
ADMAsecurities fraudchannel stuffingclass action lawsuitshort seller reportinvestor lossesmisleading business information
Sentiment note
Company faces serious allegations of channel stuffing and issuing materially misleading information to investors, resulting in a significant 16.6% stock price decline and triggering a securities class action investigation.
NegativeGlobeNewswire Inc.• The Rosen Law Firm
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm has announced an investigation into potential securities claims against ADMA Biologics, Inc. following allegations that the company engaged in channel stuffing to inflate revenue growth. A short seller report by Culper Research triggered a 16.6% stock decline on March 24, 2026. The firm is preparing a class action lawsuit to recover investor losses.
ADMAsecurities fraudchannel stuffingclass action lawsuitshort seller allegationsinvestor lossesmisleading business information
Sentiment note
Company faces allegations of channel stuffing and issuing materially misleading business information, resulting in a significant 16.6% stock price decline and triggering a securities class action investigation.
NegativeGlobeNewswire Inc.• Block & Leviton Llp
BREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover Losses
ADMA Biologics shares fell over 24% after withdrawing long-term financial guidance due to market competitive dynamics and allegations of inflated growth through channel stuffing. Primoris Services stock declined over 45%, and GeneDX shares plummeted over 45% on May 5th. Block & Leviton is investigating all three companies for potential securities law violations and encouraging affected investors to seek recovery.
Stock fell 24% after withdrawing financial guidance; allegations of inflated growth through channel stuffing and misleading business practices related to Asceniv product; securities investigation underway
NegativeGlobeNewswire Inc.• Rosen Law Firm
BSX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSX
Rosen Law Firm announces securities class action lawsuits against Boston Scientific Corporation, Camping World Holdings, Inc., and ADMA Biologics, Inc. The Boston Scientific lawsuit alleges the company made false statements about its U.S. Electrophysiology segment's sustainability while concealing material adverse facts, leading to a net income miss and underwhelming guidance. Investors who purchased shares during specified class periods are encouraged to join the litigation before upcoming deadlines.
BSXCWHADMAsecurities class actionBoston ScientificCamping World HoldingsADMA Biologicsinvestor lawsuit
Sentiment note
Company is under investigation by Rosen Law Firm for potential securities claims on behalf of shareholders, suggesting alleged violations of securities laws.
NegativeGlobeNewswire Inc.• The Rosen Law Firm
ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
The Rosen Law Firm is investigating potential securities claims against ADMA Biologics (NASDAQ: ADMA) following allegations of channel stuffing to inflate revenue growth. The stock plunged 16.6% on March 24, 2026, after short seller Culper Research released a report detailing the allegations. Investors who suffered losses are encouraged to join a prospective class action lawsuit.
ADMAsecurities fraudchannel stuffingclass action lawsuitstock declineinvestor lossesmisleading business information
Sentiment note
The company faces serious allegations of channel stuffing and issuing materially misleading business information, resulting in a significant 16.6% stock price decline and triggering a securities class action investigation.
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
